Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 6

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 6
---
 par value per share.

“Reincorporation Merger”
means the first step of the Business Combination which occurred pursuant to the Merger Agreement, in which ASCA reincorporated to the
British Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp.

“Reverse Stock Splits”
means the First Reverse Stock Split, the Second Reverse Stock Split, and the Third Reverse Stock Split. In this prospectus, where we
state historical share and per-share numbers, we have, where appropriate, reflected a retroactive adjustment due to the Reverse Stock
Splits in parentheses.

“Second Reverse Stock
Split” means the 1-for-10 reverse stock split effected by the Company on May 5, 2025.

“Third Reverse Stock
Split” means the 1-for-5 reverse stock split effected by the Company on August 4, 2025.

<div align='center'>iv

PROSPECTUS SUMMARY</div>

This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the “Risk Factors” section and the financial statements and related notes appearing at the end of this prospectus.

Unless the context otherwise
requires, all references in this Prospectus Summary to “NewGenIvf,” “we,” “our,” and “us”
refer to Legacy NewGenIvf and its subsidiaries as they existed prior to the Closing if described in relation to a date prior to April
3, 2024. Any references to “NewGenIvf,” “we,” “our,” and “us” with respect to the present
time, a future time, or a date after April 3, 2024 refers to NewGenIvf, a British Virgin Islands company, and its subsidiaries, whose
existence continued after the Closing.

Overview

We are an assisted reproductive
services (“ARS”) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourselves as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and Kyrgyzstan positions us to
take advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (“CIC”), from 2014 to 2022,
there was a rising number of women in the key ARS-targeted age group (ages 15 to 49)